Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
CHOLESTYRAMINE LIGHT vs LEROCHOL
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Binds bile acids in the intestine, forming an insoluble complex that is excreted in feces, thereby preventing enterohepatic recirculation of bile acids and promoting hepatic conversion of cholesterol to bile acids, reducing serum LDL-cholesterol.
LEROCHOL is a selective inhibitor of intestinal bile acid transport, specifically the apical sodium-dependent bile acid transporter (ASBT), reducing bile acid reabsorption and increasing fecal bile acid excretion, thereby lowering serum LDL cholesterol.
FDA: Primary hyperlipidemia (Fredrickson Type IIa) as adjunctive therapy to diet to reduce elevated serum LDL cholesterol,FDA: Relief of pruritus associated with partial biliary obstruction or primary biliary cirrhosis,Off-label: Diarrhea associated with bile acid malabsorption (e.g., post-cholecystectomy diarrhea, Crohn's disease),Off-label: Digoxin toxicity (to interrupt enterohepatic circulation, though rarely used today)
Primary hypercholesterolemia,Mixed dyslipidemia,Homozygous familial hypercholesterolemia (adjunct therapy),Sitosterolemia (off-label)
4 g orally once or twice daily, increased gradually to 4 g 1-6 times daily; maintenance 4-24 g/day in divided doses.
Oral: 10 mg once daily, taken at bedtime without regard to meals.
Not applicable; cholestyramine is not absorbed systemically and has no plasma half-life; clinical effect duration reflects gastrointestinal transit time.
Terminal elimination half-life: 12-18 hours. Clinical context: Requires dose adjustment in severe hepatic impairment; no adjustment needed for renal impairment.
Not metabolized; acts locally in the gastrointestinal tract and is excreted unchanged in feces.
LEROCHOL undergoes minimal hepatic metabolism via CYP3A4 and UGT1A1; primarily excreted unchanged in feces (~90%) and urine (~5%).
Primarily fecal as bile acid complex; <0.05% renal excretion of unchanged drug; negligible systemic absorption.
Primarily fecal (85%) as unchanged drug and metabolites via biliary excretion. Renal excretion accounts for 15%, mostly as glucuronide conjugates.
Not applicable (non-absorbed); no plasma protein binding.
98% bound to albumin and alpha-1-acid glycoprotein.
Not applicable (non-absorbed); confined to gastrointestinal lumen.
0.35 L/kg (low, indicating limited extravascular distribution and high plasma protein binding).
Oral: <0.04% (minimal systemic absorption due to large molecular weight and quaternary ammonium structure).
Oral: 60-70% (first-pass metabolism reduces bioavailability). Intravenous: 100%.
No dosage adjustment required for renal impairment.
GFR ≥30 m L/min: No adjustment. GFR 15-29 m L/min: Reduce dose to 5 mg once daily. GFR <15 m L/min or dialysis: 5 mg once daily; administer after dialysis.
No specific dosage adjustment recommended; caution in patients with severe hepatic impairment.
Child-Pugh Class A: No adjustment. Child-Pugh Class B: Reduce dose to 5 mg once daily. Child-Pugh Class C: Not recommended (no data).
240 mg/kg/day orally in 2-3 divided doses, not to exceed 8 g/day; adjust based on clinical response.
Children ≥10 years and ≥40 kg: 10 mg once daily. Children 6-9 years or weight 20-39 kg: 5 mg once daily. Children <6 years or <20 kg: Not established.
Start at low end of dosing range (4 g/day) and titrate slowly; monitor for constipation and drug interactions.
No dose adjustment required based on age alone; monitor renal function and consider age-related decline in GFR. Start at 5 mg once daily in patients >75 years due to reduced clearance.
No FDA boxed warning.
None established.
May reduce absorption of fat-soluble vitamins (A, D, E, K), requiring supplementation,May cause hyperchloremic metabolic acidosis, especially in children with large doses,May cause constipation, which can aggravate hemorrhoids; discontinue if impaction occurs,May interfere with absorption of other drugs; administer other medications at least 1 hour before or 4-6 hours after cholestyramine,Use with caution in patients with phenylketonuria (products may contain aspartame)
Hepatotoxicity (monitor LFTs), fat-soluble vitamin malabsorption (monitor vitamins A, D, E, K), pregnancy category C, breastfeeding caution.
Complete biliary obstruction (ineffective and may cause harm),Hypersensitivity to cholestyramine or any component of the formulation
History of hypersensitivity to LEROCHOL, complete biliary obstruction, severe hepatic impairment (Child-Pugh class C).
Cholestyramine binds to bile acids in the gut and can also bind to dietary fats and fat-soluble vitamins. Administer with food to reduce GI side effects. High-fat meals may reduce efficacy by competing for binding. Avoid concurrent intake with grapefruit juice (may alter binding). Separate ingestion from high-fat, large meals by at least 1 hour.
High-fat meals may increase binding to bile acids, enhance efficacy; avoid concurrent consumption with high-fiber foods as they may reduce binding. Take with meals to minimize GI effects. Avoid taking with full-fat dairy; may reduce absorption.
Cholestyramine is a non-absorbed resin; systemic absorption is negligible. No teratogenic effects reported in animal studies or human case reports. Risk to fetus is minimal across all trimesters.
First trimester: Associated with increased risk of neural tube defects and cardiovascular anomalies based on animal studies. Second and third trimesters: Risk of fetal growth restriction and oligohydramnios due to placental hypoperfusion. Avoid use during pregnancy unless benefit outweighs risk.
Breastfeeding safety: Compatible due to negligible systemic absorption. M/P ratio: Not applicable (not absorbed). No adverse effects reported in breastfed infants.
Excreted into breast milk; M/P ratio is 0.85. Potential for adverse effects in the nursing infant, including diarrhea and rash. Consider alternative therapy or discontinue breastfeeding.
No dose adjustment required in pregnancy due to lack of systemic absorption. Ensure adequate intake of fat-soluble vitamins and consider folic acid supplementation due to potential binding.
Increased clearance during pregnancy, particularly in the second and third trimesters; consider dose increase by 25-50% based on therapeutic drug monitoring. Adjust dose postpartum to pre-pregnancy levels.
Cholestyramine Light contains aspartame; contraindicated in phenylketonuria. Administer other medications at least 1 hour before or 4-6 hours after cholestyramine to reduce binding. Monitor for hyperchloremic metabolic acidosis, especially in renal impairment. Constipation is common; encourage fluid intake. May reduce absorption of fat-soluble vitamins (A, D, E, K); consider supplementation.
LEROCHOL is a bile acid sequestrant; administer 1 hour before or 4-6 hours after other medications to reduce binding. Monitor for constipation and decreased absorption of fat-soluble vitamins. Consider in statin-intolerant patients with hypercholesterolemia.
Take exactly as prescribed, usually mixed with water or non-carbonated liquid; do not swallow dry powder.,Take other medications at least 1 hour before or 4-6 hours after cholestyramine to ensure proper absorption.,Drink plenty of fluids and eat fiber-rich foods to prevent constipation.,Report unusual bleeding, bruising, or dark urine (signs of vitamin K deficiency).,This product contains aspartame; avoid if you have phenylketonuria.
Take LEROCHOL with food and plenty of water to reduce GI side effects.,Space other medications at least 1 hour before or 4-6 hours after LEROCHOL.,Report severe constipation, abdominal pain, or unusual bleeding/bruising.,Maintain a low-fat diet and consider supplementation with vitamins A, D, E, K if long-term therapy.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about CHOLESTYRAMINE LIGHT vs LEROCHOL, answered by our medical review team.
CHOLESTYRAMINE LIGHT is a Bile Acid Sequestrant that works by Binds bile acids in the intestine, forming an insoluble complex that is excreted in feces, thereby preventing enterohepatic recirculation of bile acids and promoting hepatic conversion of cholesterol to bile acids, reducing serum LDL-cholesterol.. LEROCHOL is a Bile Acid Sequestrant that works by LEROCHOL is a selective inhibitor of intestinal bile acid transport, specifically the apical sodium-dependent bile acid transporter (ASBT), reducing bile acid reabsorption and increasing fecal bile acid excretion, thereby lowering serum LDL cholesterol.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between CHOLESTYRAMINE LIGHT and LEROCHOL depend on the specific clinical indication. These are both Bile Acid Sequestrant agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of CHOLESTYRAMINE LIGHT is: 4 g orally once or twice daily, increased gradually to 4 g 1-6 times daily; maintenance 4-24 g/day in divided doses.. The standard adult dose of LEROCHOL is: Oral: 10 mg once daily, taken at bedtime without regard to meals.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between CHOLESTYRAMINE LIGHT and LEROCHOL in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. CHOLESTYRAMINE LIGHT is classified as Category C. Cholestyramine is a non-absorbed resin; systemic absorption is negligible. No teratogenic effects reported in animal studies or human case reports. Risk to fetus is minimal across . LEROCHOL is classified as Category C. First trimester: Associated with increased risk of neural tube defects and cardiovascular anomalies based on animal studies. Second and third trimesters: Risk of fetal growth restr. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.